Shopping Cart
Remove All
Your shopping cart is currently empty
Sudubrilimab (Alias: HS636)
Catalog No. T77189 Copy Product Info
🥰Excellent
Sudubrilimab is an innovative bifunctional fusion protein designed to simultaneously target two key inhibitory pathways in the tumor microenvironment: the PD-1/PD-L1 immune checkpoint and the TGF-beta signaling axis. The compound consists of a humanized anti-PD-L1 monoclonal antibody fused to the extracellular domain of TGF-beta receptor II (TGFBR2-ECD). Serving as an essential tool for investigating the reversal of tumor immunosuppression and the enhancement of effector cell function, its design aims to overcome resistance to single-target therapies through synergistic action.
Sudubrilimab
Copy Product Info🥰Excellent
Catalog No. T77189
Alias HS636
Sudubrilimab is an innovative bifunctional fusion protein designed to simultaneously target two key inhibitory pathways in the tumor microenvironment: the PD-1/PD-L1 immune checkpoint and the TGF-beta signaling axis. The compound consists of a humanized anti-PD-L1 monoclonal antibody fused to the extracellular domain of TGF-beta receptor II (TGFBR2-ECD). Serving as an essential tool for investigating the reversal of tumor immunosuppression and the enhancement of effector cell function, its design aims to overcome resistance to single-target therapies through synergistic action.
Sudubrilimab
Cas No. 2387417-06-1
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 5 mg | Inquiry | Inquiry | Inquiry |
In stock · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Sudubrilimab is an innovative bifunctional fusion protein designed to simultaneously target two key inhibitory pathways in the tumor microenvironment: the PD-1/PD-L1 immune checkpoint and the TGF-beta signaling axis. The compound consists of a humanized anti-PD-L1 monoclonal antibody fused to the extracellular domain of TGF-beta receptor II (TGFBR2-ECD). Serving as an essential tool for investigating the reversal of tumor immunosuppression and the enhancement of effector cell function, its design aims to overcome resistance to single-target therapies through synergistic action. |
| In vitro | In PD-L1 and TGF-beta binding assays, Sudubrilimab bound specifically to both targets and enhanced IFN-gamma production in T-cell activation assays [1]. |
| Synonyms | HS636 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | PD-L1 |
| Cas No. | 2387417-06-1 |
| Isotype | IgG1 |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Sudubrilimab | purchase Sudubrilimab | Sudubrilimab cost | order Sudubrilimab | Sudubrilimab in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.